Related Experiment Video
Updated: May 28, 2026
14:27
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
Clinical heterogeneity and outcome of acquired PRCA: a multicenter European study
Francesco Versino1,2, Marc Michel3, Jennifer Vidler4
1Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Blood Advances
|May 27, 2026
Summary
Pure red cell aplasia (PRCA) is a rare bone marrow failure. Immunosuppression, particularly cyclosporine A, is effective, with mTOR inhibitors showing promise for refractory cases.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Pure red cell aplasia (PRCA) is a rare bone marrow failure disorder characterized by anemia and reduced erythroid precursors.
- Diagnosis is challenging due to heterogeneous causes, including thymoma, autoimmune diseases, T-cell large granular lymphocyte (T-LGL) expansion, and myelodysplastic syndromes (MDS).
- Limited evidence guides management due to the disease's rarity and lack of prospective studies.
Purpose of the Study:
- To analyze clinical characteristics, diagnostic approaches, and treatment outcomes in acquired adult PRCA.
- To evaluate the efficacy of immunosuppressive therapies, including cyclosporine A (CyA) and mTOR inhibitors.
- To investigate the role of molecular analyses and identify factors influencing mortality.
Main Methods:
- Multicenter retrospective analysis of 121 acquired adult PRCA cases (excluding parvovirus B19-associated PRCA) across 14 European centers.
- Bone marrow immunohistochemistry and next-generation sequencing (NGS) were performed.
- Treatment strategies included immunosuppression (cyclosporine A, mTOR inhibitors) and supportive care.
Main Results:
- Secondary PRCA accounted for 78% of cases, with thymoma (23%) and MDS (21%) being the most frequent causes.
- Immunosuppression, especially early-initiated CyA, showed significant overall response rates (61%) and complete response rates (47%).
- mTOR inhibitors demonstrated promising activity (71% response rate) as second-line therapy for CyA-refractory cases. Mortality was 30%, primarily due to infections, and higher in MDS-associated PRCA.
Conclusions:
- PRCA is a diagnostically complex and heterogeneous disorder requiring integrated molecular analyses for accurate diagnosis and stratification.
- Immunosuppression is the cornerstone of PRCA treatment, with CyA as a reliable first-line option and mTOR inhibitors as effective rescue therapies.
- Early diagnosis and treatment initiation are crucial for improving outcomes in PRCA.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...